<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id><journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id><journal-id journal-id-type="publisher-id">nss</journal-id><journal-title-group><journal-title>Nature and Science of Sleep</journal-title></journal-title-group><issn pub-type="epub">1179-1608</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39399825</article-id><article-id pub-id-type="pmc">11470772</article-id><article-id pub-id-type="publisher-id">481010</article-id><article-id pub-id-type="doi">10.2147/NSS.S481010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Survival and Risk Factors Associated with Mortality in Patients with Sleep Apnoea in Colombia: A Retrospective Cohort Study</article-title><alt-title alt-title-type="running-authors">Tuta-Quintero et al</alt-title><alt-title alt-title-type="running-title">Tuta-Quintero et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tuta-Quintero</surname><given-names>Eduardo</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bastidas</surname><given-names>Alirio R</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-5548-3464</contrib-id><name><surname>Faizal-Gómez</surname><given-names>Kamil</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1556-7205</contrib-id><name><surname>Torres-Riveros</surname><given-names>Sergio Guillermo</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4118-2221</contrib-id><name><surname>Rodríguez-Barajas</surname><given-names>Diego Alejandro</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6301-4923</contrib-id><name><surname>Guezguan</surname><given-names>Jonathan Alexander</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7348-9199</contrib-id><name><surname>Muñoz</surname><given-names>Laura D</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rojas</surname><given-names>Ana Carolina</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-5743-4057</contrib-id><name><surname>Hernández Calderón</surname><given-names>Katherine</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ardila Velasco</surname><given-names>Natalia Valentina</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Prieto</surname><given-names>Paula</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cuestas</surname><given-names>Juliana</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Camacho-Osorio</surname><given-names>Julian</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bonilla</surname><given-names>Gabriela</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Collazos Bahamon</surname><given-names>Estefania</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guardiola</surname><given-names>María Alejandra</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0004-6575-3369</contrib-id><name><surname>Luna Salazar</surname><given-names>David</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fajardo</surname><given-names>Lina Paola</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rincón-Hernández</surname><given-names>Johan</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Facultad de Medicina, Universidad de La Sabana</institution>, <addr-line>Chía</addr-line>, <country>Colombia</country></aff><aff id="aff0002"><label>2</label><institution>Residente de Medicina Interna, Facultad de Medicina, Universidad de La Sabana</institution>, <addr-line>Chía</addr-line>, <country>Colombia</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Alirio R Bastidas, <institution>School of Medicine, Universidad de La Sabana</institution>, <addr-line>Km 7, Autonorte de Bogota</addr-line>, <addr-line>Chía</addr-line>, <addr-line>Cundinamarca</addr-line>, <addr-line>250001</addr-line>, <country>Colombia</country>, Email alirio.bastidas@unisabana.edu.co</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>16</volume><fpage>1601</fpage><lpage>1610</lpage><history><date date-type="received"><day>02</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>© 2024 Tuta-Quintero et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Tuta-Quintero et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec><title>Background</title><p><citation_analysis attribute="neither">Survival in patients with sleep apnoea (SA) can be reduced by variables such as age, sex, and comorbidities. However, survival data in patients with SA in Colombia remains scarce.</citation_analysis></p></sec><sec><title>Methods</title><p><citation_analysis attribute="positive">This is a retrospective cohort study of patients diagnosed with SA between 2005 and 2022. Five-year survival was assessed using the Kaplan-Meier method, and survival curves were stratified by age, sex, and cardiovascular disease. Risk factors associated with survival were evaluated using Hazard Ratio (HR) by adjusting for confounding variables with a Cox regression model. A minimum sample size of 1537 patients were estimated to be necessary to estimate a survival incidence rate with a 5% precision.</citation_analysis></p></sec><sec><title>Results</title><p><citation_analysis attribute="neither">The five-year survival rate in the general population was 94.6%, with lower survival in patients over 65 years (88.5% vs 97.9%; p &lt; 0.001) and in patients with cardiovascular disease (89% vs 95.2%; p &lt; 0.001) compared to the control group. In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02–1.07; p &lt; 0.001). Male sex had an HR of 2.31 (95% CI: 1.25–4.25; p = 0.007), congestive heart failure an HR of 4.00 (95% CI: 2.31–6.94; p &lt; 0.001), chronic obstructive pulmonary disease (COPD) an HR of 1.75 (95% CI: 1.04–2.96; p = 0.035), chronic kidney disease (CKD) an HR of 2.23 (95% CI: 1.31–3.78; p = 0.003), and metastatic cancer an HR of 4.96 (95% CI: 1.95–12.60; p = 0.001).</citation_analysis></p></sec><sec><title>Conclusion</title><p><citation_analysis attribute="negative">The study showed a high five-year survival rate in patients with SA. The risk factors associated with decreased overall five-year survival were age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer.</citation_analysis></p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>sleep apnoea</kwd><kwd>survival</kwd><kwd>risk factors</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Universidad de la Saban</institution></institution-wrap>
</funding-source></award-group><funding-statement>This work was supported by Universidad de la Sabana Grant (MEDESP-5-2024).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><ref-count count="33"/><page-count count="10"/></counts></article-meta></front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Sleep apnoea (SA) is a chronic condition characterized by recurrent episodes of upper airway obstruction during sleep, leading to transient breathing interruptions and intermittent hypoxemia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither"> This condition is significantly associated with reduced survival and an increased incidence of cardiovascular disease such as acute myocardial infarction, stroke, and cardiac arrhythmias.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis><citation_analysis attribute="positive"> Worldwide epidemiological studies have documented a relationship between SA and increased mortality, highlighting the need for research to describe survival rates and identify factors influencing survival in this population.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1–5</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">It is estimated that around one billion adults aged 30 to 69 worldwide suffer from SA, with a prevalence exceeding 50% in some countries.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6–10</xref></citation_analysis><citation_analysis attribute="neither"> In South America, Tufik et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither"> conducted 1042 polysomnographies in a population from São Paulo, finding a prevalence of 32.8% (95% CI, 29.6–36.3%) for SA. The variables associated with this prevalence were being male (OR = 4.1; 95% CI, 2.9–5.8; P &lt; 0.001) and obesity (OR = 10.5; 95% CI, 7.1–15.7; P &lt; 0.001).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither"> Young et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="positive"> in a cohort of 1522 patients with an 18-year follow-up, identified a significant association between SA severity and mortality (HR 2.65; 95% CI, 1.82 to 3.85; p &lt; 0.001). Similar data were described by “The Busselton Health Study”, a longitudinal study with an average follow-up of 13.4 years that included 380 patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="negative"> This study identified moderate to severe SA as an independent factor for a higher risk of all-cause mortality (HR = 6.24; 95% CI, 2.01 to 19.39) compared to those without SA (HR = 0.47; 95% CI, 0.17 to 1.29) (p &lt; 0.008).</citation_analysis></p>
      <p><citation_analysis attribute="neither">Pre-existing cardiovascular disease increases mortality in patients with SA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="positive"> The study “Influence of Obstructive Sleep Apnea on Mortality in Patients With Heart Failure”, which followed 164 patients with a left ventricular ejection fraction &lt;45% for up to 7.3 years, found a significant association between the presence of SA and a higher risk of mortality in patients with heart failure.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither"> Ge et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="positive"> concluded that the presence of acute myocardial infarction (AMI) and a decreased LVEF increased mortality by 1.90 times (95% CI, 1.82–3.85) in patients with SA. These findings suggest that the severity of SA may be an important risk factor for cardiovascular mortality.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> Additionally, other conditions such as chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), collagen diseases, and type 2 diabetes have also been associated with increased mortality in these patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">SA is characterized by episodes of intermittent hypoxemia and sleep fragmentation, both factors associated with increased mortality through various pathophysiological mechanisms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12–14</xref></citation_analysis><citation_analysis attribute="neither"> Oxygen desaturation during apneas or hypopneas triggers nocturnal activation of the sympathetic nervous system and initiates an inflammatory cascade, including cellular oxidative stress.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither"> These mechanisms contribute to the accelerated development of cardiovascular diseases and the mortality associated with SA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither"> Currently, it has been described that survival in patients with SA is influenced by variables such as age, sex, and comorbidities.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="positive"> However, data on survival in patients with SA, particularly in Latin American countries, remain scarce, necessitating the description of variables associated with outcomes in this population. The main objective of this study is to determine the factors associated with mortality and five-year survival in patients diagnosed with SA in Colombia.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Methods</title>
      <p><citation_analysis attribute="positive">A retrospective cohort study was conducted on subjects treated at the Clínica Universidad de La Sabana in Chía, Colombia, from 2005 to 2022. The main objective of the study was to evaluate the survival of patients diagnosed with SA and describe the factors associated with mortality.</citation_analysis></p>
      <sec id="s0002-s2001">
        <title>Eligibility Criteria</title>
        <p><citation_analysis attribute="neither">Patients aged 18 years or older with a diagnosis of obstructive sleep apnea (OSA), defined by an apnoea-hypopnea index (AHI) greater than 5 events per hour of sleep, as confirmed by polysomnography (PSG) following American Academy of Sleep Medicine (AASM) criteria, were included.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither"> Eligible patients presented with symptoms such as chronic snoring, excessive daytime sleepiness, persistent fatigue, and sleep disturbances.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="positive"> Exclusion criteria included other sleep disorders or medical conditions with similar symptoms, as well as patients lacking follow-up survival data, and incomplete AHI information.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2002">
        <title>Variables and Data Collection</title>
        <p><citation_analysis attribute="positive">Variables analyzed included age, sex, race, marital status, anthropometric measures, and medical history of diseases such as congestive heart failure (CHF), atrial fibrillation (AF), cerebrovascular disease (CVE), CKD, COPD, AMI, and cancer. PSG variables analyzed included AHI, type of apnea, and the presence of restless legs syndrome. Regarding oxygen therapy prescription, the time from initiation, hours prescribed, hours used per day, and flow in liters were considered. Additionally, speech therapy indications and positive airway pressure system variables, such as Bi-Level Positive Airway Pressure (BPAP), Continuous Positive Airway Pressure (CPAP), and Automatic Continuous Positive Airway Pressure (AUTOCPAP) were considered. The outcome variable was survival, evaluated at 5 years.</citation_analysis></p>
        <p><citation_analysis attribute="positive">Data evaluation and collection were performed using a database directly obtained from electronic medical records and diagnostic test results. To identify the follow-up status of patients, the general health system resource administrator (ADRES) was consulted to report the survival status. Precise eligibility criteria were established to mitigate selection bias. To reduce transcription bias, at least two team members reviewed the information, and in case of inconsistency, a third team member reviewed the information and made the final decision. Additionally, all variables were clearly defined, and the researchers responsible for data collection were previously trained.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Statistical Analysis</title>
      <p><citation_analysis attribute="neither">Data were transcribed into the Research Electronic Data Capture (REDCap) software version.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="positive"> Quantitative variables were summarized using measures of central tendency and dispersion, with means and standard deviations (SD) for normally distributed data, and medians and interquartile ranges (IQR) for non-normally distributed data. The Shapiro–Wilk test was used to assess normality. Qualitative variables were described as absolute and relative frequencies. Univariate analysis between study variables and the presence or absence of SA was performed using the chi-square test for qualitative variables and the Student’s </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">t</italic></citation_analysis><citation_analysis attribute="neither">-test or Mann–Whitney </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">U</italic></citation_analysis><citation_analysis attribute="neither">-test depending on the distribution of quantitative variables.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Five-year survival was assessed using survival tables, and the results were plotted using the Kaplan-Meier method.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="positive"> Survival curves were stratified by age, sex, and cardiovascular disease (AMI, CHF, AF, and CVE). Time to death was used as the dependent variable in the Cox regression model with variables selected for inclusion through bivariate analysis using a significance threshold of p &lt; 0.2 and their biological plausibility in relation to the event in question. We built the covariate-adjusted model and created a series of directed acyclic graphs (DAGs) through an iterative process. Subsequently, we evaluated each covariate considered relevant for our analysis based on its association with the outcome using univariable Cox regressions with a significance level of α = 0.50. These covariates were considered for the multivariable model.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="positive"> Once the full model was fitted to the data, we used a stepwise backward regression method for variable selection. We started with a saturated model that included all possible variables and, at each step, removed the least significant variable until all remaining variables were significant according to adjustment criteria, such as the p-value, and based on clinical considerations.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither"> Regression coefficients and corresponding p-values were calculated for each independent variable.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither"> Hazard ratios (HR) for each variable were determined, with a significance level of p &lt; 0.05 considered statistically relevant.</citation_analysis></p>
      <p><citation_analysis attribute="neither">To determine the required sample size, we applied the Schoenfeld formula for survival analysis with an alpha level of 0.05 and 90% power.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="positive"> Based on this calculation, a minimum sample size of 1537 patients was estimated to achieve a 5% precision in estimating the survival incidence rate. This estimate considers the prevalence of significant comorbidities within our study setting.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="positive"> Data were analyzed using IBM SPSS software (version 26, IBM Corp., Chicago, IL, USA), which was licensed to the researchers’ university.</citation_analysis></p>
    </sec>
    <sec id="s0004">
      <title>Results</title>
      <sec id="s0004-s2001">
        <title>General Characteristics of the Population</title>
        <p><citation_analysis attribute="neither">A total of 2,027 patients diagnosed with SA were included, with an average age of 57.4 years (SD 15.52) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">). Males constituted 73.5% (1,413/2,027) of the sample and had an average body mass index (BMI) of 29 kg/m² (SD 4.82) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither">). In the study population, 53.4% (1,083/2,027) had a history of systemic arterial hypertension, and 17.2% (348/2,027) had COPD. Among patients with COPD, 15.1% (291/1,922) survived, while 54.3% (57/105) died (p &lt; 0.001).</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0001"><label>Table 1</label><caption><p><citation_analysis attribute="neither">General Characteristics of the Population</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th rowspan="1" colspan="1">Total Population</th><th rowspan="1" colspan="1">Alive</th><th rowspan="1" colspan="1">Dead</th><th rowspan="2" colspan="1">p Value</th></tr><tr><th rowspan="1" colspan="1">n= 2027</th><th rowspan="1" colspan="1">n= 1922</th><th rowspan="1" colspan="1">n= 105</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age years, m (SD)</td><td rowspan="1" colspan="1">57.4 (15.52)</td><td rowspan="1" colspan="1">56.6 (15.21)</td><td rowspan="1" colspan="1">71.8 (13.99)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">&gt;65 years, n (%)</td><td rowspan="1" colspan="1">707 (34.9)</td><td rowspan="1" colspan="1">630 (32.8)</td><td rowspan="1" colspan="1">77 (73.3)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Male sex, n (%)</td><td rowspan="1" colspan="1">1497 (73.9)</td><td rowspan="1" colspan="1">1413 (73.5)</td><td rowspan="1" colspan="1">84 (80)</td><td rowspan="1" colspan="1">0.141</td></tr><tr><td rowspan="1" colspan="1">Weight Kilograms, m (SD)</td><td rowspan="1" colspan="1">79.7 (15.14)</td><td rowspan="1" colspan="1">79.9 (15.14)</td><td rowspan="1" colspan="1">75.9 (14.53)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td rowspan="1" colspan="1">Size meters, m (SD)</td><td rowspan="1" colspan="1">1.7 (0.09)</td><td rowspan="1" colspan="1">1.7 (0.09)</td><td rowspan="1" colspan="1">1.6 (0.08)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td rowspan="1" colspan="1">BMI Kg/m<sup>2</sup>, m (SD)</td><td rowspan="1" colspan="1">29 (4.82)</td><td rowspan="1" colspan="1">29 (4.77)</td><td rowspan="1" colspan="1">28.5 (5.61)</td><td rowspan="1" colspan="1">0.321</td></tr><tr><td rowspan="1" colspan="1">Smoking, n (%)</td><td rowspan="1" colspan="1">843 (41.6)</td><td rowspan="1" colspan="1">779 (40.5)</td><td rowspan="1" colspan="1">64 (61)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Hypertension, n (%)</td><td rowspan="1" colspan="1">1083 (53.4)</td><td rowspan="1" colspan="1">998 (51.9)</td><td rowspan="1" colspan="1">85 (81)</td><td rowspan="1" colspan="1">0.276</td></tr><tr><td rowspan="1" colspan="1">Depression, n (%)</td><td rowspan="1" colspan="1">129 (6.4)</td><td rowspan="1" colspan="1">121 (6.3)</td><td rowspan="1" colspan="1">8 (7.6)</td><td rowspan="1" colspan="1">0.589</td></tr><tr><td rowspan="1" colspan="1">Alcohol consumption, n (%)</td><td rowspan="1" colspan="1">125 (6.2)</td><td rowspan="1" colspan="1">107 (5.6)</td><td rowspan="1" colspan="1">18 (17.1)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Acute myocardial infarction, n (%)</td><td rowspan="1" colspan="1">207 (10.2)</td><td rowspan="1" colspan="1">185 (9.6)</td><td rowspan="1" colspan="1">22 (21)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Atrial fibrillation, n (%)</td><td rowspan="1" colspan="1">109 (5.4)</td><td rowspan="1" colspan="1">86 (4.5)</td><td rowspan="1" colspan="1">23 (21.9)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Congestive heart failure, n (%)</td><td rowspan="1" colspan="1">167 (8.2)</td><td rowspan="1" colspan="1">125 (6.5)</td><td rowspan="1" colspan="1">42 (40)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Peripheral vascular disease, n (%)</td><td rowspan="1" colspan="1">70 (3.5)</td><td rowspan="1" colspan="1">60 (3.1)</td><td rowspan="1" colspan="1">10 (9.5)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Cerebrovascular disease, n (%)</td><td rowspan="1" colspan="1">133 (6.6)</td><td rowspan="1" colspan="1">115 (6)</td><td rowspan="1" colspan="1">18 (17.1)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">COPD, n (%)</td><td rowspan="1" colspan="1">348 (17.2)</td><td rowspan="1" colspan="1">291 (15.1)</td><td rowspan="1" colspan="1">57 (54.3)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Connective tissue disease, n (%)</td><td rowspan="1" colspan="1">83 (4.1)</td><td rowspan="1" colspan="1">71 (3.7)</td><td rowspan="1" colspan="1">12 (11.4)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Liver disease, n (%)</td><td rowspan="1" colspan="1">19 (0.9)</td><td rowspan="1" colspan="1">15 (0.8)</td><td rowspan="1" colspan="1">4 (3.8)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Diabetes, n (%)</td><td rowspan="1" colspan="1">336 (16.6)</td><td rowspan="1" colspan="1">297 (15.5)</td><td rowspan="1" colspan="1">39 (37.1)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease, n (%)</td><td rowspan="1" colspan="1">120 (5.9)</td><td rowspan="1" colspan="1">92 (4.8)</td><td rowspan="1" colspan="1">28 (26.7)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Cancer without metastasis, n (%)</td><td rowspan="1" colspan="1">142 (0)</td><td rowspan="1" colspan="1">118 (6.1)</td><td rowspan="1" colspan="1">24 (22.9)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Cancer with metastasis, n (%)</td><td rowspan="1" colspan="1">19 (0.9)</td><td rowspan="1" colspan="1">9 (0.5)</td><td rowspan="1" colspan="1">10 (9.5)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Traffic accidents, n (%)</td><td rowspan="1" colspan="1">79 (3.9)</td><td rowspan="1" colspan="1">69 (3.6)</td><td rowspan="1" colspan="1">10 (9.5)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">History of CV disease (%)</td><td rowspan="1" colspan="1">446 (22)</td><td rowspan="1" colspan="1">390 (20.3)</td><td rowspan="1" colspan="1">56 (53.3)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: m, media; SD, Standard deviation; COPD, Chronic obstructive pulmonary disease; CV, Cardiovascular.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p><citation_analysis attribute="neither">Flowchart of study.</citation_analysis></p></caption><graphic xlink:href="NSS-16-1601-g0001" content-type="print-only" position="float"/></fig></citation_analysis></p>
        <sec id="s0004-s2001-s3001">
          <title>Polysomnography</title>
          <p><citation_analysis attribute="neither">The average AHI of the general population was 37.1 (SD 24.79), 36.7 (SD 24.65) in living patients, and 44.9 (SD 26.41) in deceased patients (p &lt; 0.001). Positive pressure therapy was indicated for 80% (1,622/2,027) of the general population. CPAP usage was 79.5% (1,528/1,922) in living patients compared to 89.5% (94/105) in deceased patients (p = 0.012). The characteristics of the polysomnographies performed on the population are described in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0002"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Polysomnographic Characteristics</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th rowspan="1" colspan="1">Total Population</th><th rowspan="1" colspan="1">Alive</th><th rowspan="1" colspan="1">Dead</th><th rowspan="2" colspan="1">p Value</th></tr><tr><th rowspan="1" colspan="1">n= 2027</th><th rowspan="1" colspan="1">n= 1922</th><th rowspan="1" colspan="1">n= 105</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AHI at baseline, m (SD)</td><td rowspan="1" colspan="1">37.1 (24.79)</td><td rowspan="1" colspan="1">36.7 (24.65)</td><td rowspan="1" colspan="1">44.9 (26.41)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">AHI at follow-up, m (SD)</td><td rowspan="1" colspan="1">30.6 (25.7)</td><td rowspan="1" colspan="1">30 (25.51)</td><td rowspan="1" colspan="1">40.6 (27.55)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Positive pressure requirement, n (%)</td><td rowspan="1" colspan="1">1622 (80)</td><td rowspan="1" colspan="1">1528 (79.5)</td><td rowspan="1" colspan="1">94 (89.5)</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">O<sub>2</sub>requirement, n (%)</td><td rowspan="1" colspan="1">311 (15.3)</td><td rowspan="1" colspan="1">255 (13.3)</td><td rowspan="1" colspan="1">56 (53.3)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Formulated daily hours of O<sub>2</sub> at baseline, m (SD)</td><td rowspan="1" colspan="1">16.9 (6.46)</td><td rowspan="1" colspan="1">16.9 (6.47)</td><td rowspan="1" colspan="1">16.6 (6.5)</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">Daily hours of O<sub>2</sub> use at baseline, m (SD)</td><td rowspan="1" colspan="1">17.8 (6.19)</td><td rowspan="1" colspan="1">18 (6.35)</td><td rowspan="1" colspan="1">16.9 (5.48)</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">O<sub>2</sub> flow l/min at baseline, m (SD)</td><td rowspan="1" colspan="1">2.1 (0.98)</td><td rowspan="1" colspan="1">2.1 (1.07)</td><td rowspan="1" colspan="1">2.09 (0.41)</td><td rowspan="1" colspan="1">0.094</td></tr><tr><td rowspan="1" colspan="1">Formulated daily hours of O<sub>2</sub> at follow-up, m (SD)</td><td rowspan="1" colspan="1">17.3 (6.67)</td><td rowspan="1" colspan="1">17.3 (6.72)</td><td rowspan="1" colspan="1">17.3 (6.53)</td><td rowspan="1" colspan="1">0.991</td></tr><tr><td rowspan="1" colspan="1">Daily hours of O<sub>2</sub> use during follow-up, m (SD)</td><td rowspan="1" colspan="1">18.5 (6.46)</td><td rowspan="1" colspan="1">18.8 (6.51)</td><td rowspan="1" colspan="1">17.5 (6.31)</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">O<sub>2</sub> flow l/min at follow-up, m (SD)</td><td rowspan="1" colspan="1">2 (0.53)</td><td rowspan="1" colspan="1">2.09 (0.54)</td><td rowspan="1" colspan="1">2.1 (0.49)</td><td rowspan="1" colspan="1">0.459</td></tr><tr><td rowspan="1" colspan="1">CPAP requirement n (%)</td><td rowspan="1" colspan="1">1029 (50.8)</td><td rowspan="1" colspan="1">973 (50.6)</td><td rowspan="1" colspan="1">56 (53.3)</td><td rowspan="1" colspan="1">0.589</td></tr><tr><td rowspan="1" colspan="1">CPAP pressure cmH<sub>2</sub>O at baseline, m (SD)</td><td rowspan="1" colspan="1">10.1 (2.86)</td><td rowspan="1" colspan="1">10.1 (2.86)</td><td rowspan="1" colspan="1">10.8 (2.82)</td><td rowspan="1" colspan="1">0.015</td></tr><tr><td rowspan="1" colspan="1">CPAP pressure cmH<sub>2</sub>O at follow-up, m (SD)</td><td rowspan="1" colspan="1">10.2 (2.9)</td><td rowspan="1" colspan="1">10.1 (2.9)</td><td rowspan="1" colspan="1">10.8 (2.76)</td><td rowspan="1" colspan="1">0.018</td></tr><tr><td rowspan="1" colspan="1">AutoCPAP requirement n (%)</td><td rowspan="1" colspan="1">88 (4.3)</td><td rowspan="1" colspan="1">78 (4.1)</td><td rowspan="1" colspan="1">10 (9.5)</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Upper autoCPAP pressure cmH<sub>2</sub>O at baseline, m (SD)</td><td rowspan="1" colspan="1">13.2 (4.01)</td><td rowspan="1" colspan="1">13.1 (4.08)</td><td rowspan="1" colspan="1">13.4 (3.5)</td><td rowspan="1" colspan="1">0.492</td></tr><tr><td rowspan="1" colspan="1">Lower autoCPAP pressure cmH<sub>2</sub>O at baseline, m (SD)</td><td rowspan="1" colspan="1">6.7 (2.28)</td><td rowspan="1" colspan="1">6.7 (2.33)</td><td rowspan="1" colspan="1">6.8 (1.83)</td><td rowspan="1" colspan="1">0.690</td></tr><tr><td rowspan="1" colspan="1">Upper autoCPAP pressure cmH<sub>2</sub>O at follow-up, m (SD)</td><td rowspan="1" colspan="1">13.6 (3.91)</td><td rowspan="1" colspan="1">13.5 (4)</td><td rowspan="1" colspan="1">14.6 (2.99)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Lower autoCPAP cmH<sub>2</sub>O pressure at follow-up, m (SD)</td><td rowspan="1" colspan="1">6.9 (2.49)</td><td rowspan="1" colspan="1">6.9 (2.59)</td><td rowspan="1" colspan="1">7.4 (1.13)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">BPAP requirement n (%)</td><td rowspan="1" colspan="1">216 (10.7)</td><td rowspan="1" colspan="1">194 (10.1)</td><td rowspan="1" colspan="1">22 (21)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">IPAP cmH<sub>2</sub>O at baseline, m (SD)</td><td rowspan="1" colspan="1">16.2 (3.9)</td><td rowspan="1" colspan="1">16.2 (3.85)</td><td rowspan="1" colspan="1">16.1 (4.48)</td><td rowspan="1" colspan="1">0.685</td></tr><tr><td rowspan="1" colspan="1">EPAP cmH<sub>2</sub>O at baseline, m (SD)</td><td rowspan="1" colspan="1">11.5 (3.74)</td><td rowspan="1" colspan="1">11.6 (3.78)</td><td rowspan="1" colspan="1">10.9 (3.42)</td><td rowspan="1" colspan="1">0.077</td></tr><tr><td rowspan="1" colspan="1">IPAP cmH<sub>2</sub>O at follow-up, m (SD)</td><td rowspan="1" colspan="1">16.3 (3.86)</td><td rowspan="1" colspan="1">16.4 (3.87)</td><td rowspan="1" colspan="1">15.4 (3.79)</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">EPAP cmH<sub>2</sub>O at follow-up, m (SD)</td><td rowspan="1" colspan="1">11.7 (3.57)</td><td rowspan="1" colspan="1">11.8 (3.56)</td><td rowspan="1" colspan="1">10.7 (3.62)</td><td rowspan="1" colspan="1">0.428</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">:m, media; SD, Standard deviation;O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, oxygen; l, liters; min, minutes; CPAP, Continuous Positive Airway Pressure; autoCPAP, Automatic Continuous Positive Airway Pressure; BPAP, Bi-Level Positive Airway Pressure; IPAP, Inspiratory Positive Airway Pressure; EPAP, Expiratory Positive Airway Pressure.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
        </sec>
      </sec>
      <sec id="s0004-s2002">
        <title>Five-Year Survival</title>
        <p><citation_analysis attribute="neither">The five-year survival rate in the general population was 94.6% (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0002" ref-type="fig">Figure 2</xref></citation_analysis><citation_analysis attribute="positive">), with no significant differences between men (94.1%) and women (95.8%) (p = 0.144) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0003" ref-type="fig">Figure 3</xref></citation_analysis><citation_analysis attribute="positive">). However, there was a significant decrease in survival in patients over 65 years old (88.5%) compared to those under 65 years old (97.9%) (p &lt; 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0004" ref-type="fig">Figure 4</xref></citation_analysis><citation_analysis attribute="neither">). Similarly, the presence of cardiovascular disease was associated with lower survival (89%) compared to patients without this comorbidity (95.2%) (p &lt; 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0005" ref-type="fig">Figure 5</xref></citation_analysis><citation_analysis attribute="neither">).
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p><citation_analysis attribute="neither">Survival at 5 years of follow-up.</citation_analysis></p></caption><graphic xlink:href="NSS-16-1601-g0002" content-type="print-only" position="float"/></fig></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p><citation_analysis attribute="neither">Survival at 5 years of follow-up stratified by sex.</citation_analysis></p></caption><graphic xlink:href="NSS-16-1601-g0003" content-type="print-only" position="float"/></fig></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0004" fig-type="figure"><label>Figure 4</label><caption><p><citation_analysis attribute="neither">Survival at 5 years of follow-up stratified by age.</citation_analysis></p></caption><graphic xlink:href="NSS-16-1601-g0004" content-type="print-only" position="float"/></fig></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0005" fig-type="figure"><label>Figure 5</label><caption><p><citation_analysis attribute="neither">Survival at 5 years of follow-up stratified by cardiovascular disease.</citation_analysis></p></caption><graphic xlink:href="NSS-16-1601-g0005" content-type="print-only" position="float"/><attrib><bold>Abbreviation</bold>: CVD, Cardiovascular disease.</attrib></fig></citation_analysis></p>
        <p><citation_analysis attribute="neither">In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02–1.07; p &lt; 0.001). Male sex had an HR of 2.31 (95% CI: 1.25–4.25; p = 0.007), CHF had an HR of 4.00 (95% CI: 2.31–6.94; p &lt; 0.001), COPD had an HR of 1.75 (95% CI: 1.04–2.96; p = 0.035), connective tissue disease had an HR of 1.99 (95% CI: 0.96–4.10; p = 0.064), CKD had an HR of 2.23 (95% CI: 1.31–3.78; p = 0.003), and metastatic cancer had an HR of 4.96 (95% CI: 1.95–12.60; p = 0.001) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0003" ref-type="table">Table 3</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0003"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Cox Regression: Independently Associated Characteristics with Mortality</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">HR</th><th colspan="2" rowspan="1">95 CI</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age years</td><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">1.02</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">2.31</td><td rowspan="1" colspan="1">1.25</td><td rowspan="1" colspan="1">4.25</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Congestive heart failure</td><td rowspan="1" colspan="1">4.00</td><td rowspan="1" colspan="1">2.31</td><td rowspan="1" colspan="1">6.94</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td rowspan="1" colspan="1">1.75</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">2.96</td><td rowspan="1" colspan="1">0.035</td></tr><tr><td rowspan="1" colspan="1">Connective tissue disease</td><td rowspan="1" colspan="1">1.99</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">4.10</td><td rowspan="1" colspan="1">0.064</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease</td><td rowspan="1" colspan="1">2.23</td><td rowspan="1" colspan="1">1.31</td><td rowspan="1" colspan="1">3.78</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">Metastatic cancer</td><td rowspan="1" colspan="1">4.96</td><td rowspan="1" colspan="1">1.95</td><td rowspan="1" colspan="1">12.60</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td colspan="2" rowspan="1"/><td colspan="3" rowspan="1">Concordance: 74%, p-value: &lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><citation_analysis attribute="positive"><bold>Abbreviation</bold></citation_analysis><citation_analysis attribute="neither">: HR, Hazard Ratio.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0005">
      <title>Discussion</title>
      <p><citation_analysis attribute="positive">In this study, a high five-year survival rate was observed in the general population. Survival decreased in patients over 65 years old and those with cardiovascular disease. Multivariate analysis revealed that advanced age, male sex, CHF, COPD, CKD, and metastatic cancer were associated with an increased risk of mortality, highlighting the influence of these variables on survival. These findings are relevant for considering demographic factors and comorbidities in the prognostic evaluation of patients.</citation_analysis></p>
      <p><citation_analysis attribute="positive">In a study conducted in four Latin American cities Mexico City (Mexico), Montevideo (Uruguay), Santiago (Chile), and Caracas (Venezuela)—Bouscoulet et al reported a high prevalence of SA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="positive"> This prevalence ranged from 2.9% in subjects who did not report snoring, excessive daytime sleepiness, or observed apneas, to 23.5% in those who exhibited all three symptoms. Additionally, 60.2% (95% CI: 58.8% to 61.6%) of the participants reported snoring, 34.7% (95% CI: 33.3% to 36%) suffered from insomnia, 29.2% (95% CI: 27.7% to 30.6%) took daytime naps, and 3.4% (95% CI: 2.9% to 4%) presented with a combination of snoring, sleepiness, and observed apneas. In our study, we used a lower diagnostic threshold compared to that described by Bouscoulet et al, which may have increased the reported prevalence by including a greater number of patients with mild forms of the disease.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Jara et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither"> conducted a retrospective study on the survival of patients with SA and found that five-year survival is high. Factors such as CPAP use increased survival, with 76% without CPAP and 84% with CPAP (p &lt; 0.001). In our study, higher survival was found in patients with SA (94.6%), and variables such as age over 65 and cardiovascular disease affect survival.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither"> In patients with SA, the interaction between intermittent hypoxemia and sleep fragmentation can amplify their individual effects, intensifying the inflammatory response and oxidative stress.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12–15</xref></citation_analysis><citation_analysis attribute="negative"> This synergy contributes to a greater cardiovascular morbidity burden and an increased risk of mortality.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">In a retrospective cohort study, Jennum et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="positive"> found that women with SA syndrome had lower mortality than men, even if they did not receive CPAP treatment. Factors such as younger age, being female, having a higher educational level, and low previous comorbidity, assessed using the Charlson comorbidity index for the last three years, were positively associated with survival. In contrast, being male, being 60 years or older, not receiving CPAP treatment, having a higher previous comorbidity burden, and a low educational level were identified as negative predictors of survival. According to our results and the literature, being male is a risk factor for increased mortality in patients diagnosed with SA, even when adjusted for confounding factors. Sex may influence mortality outcomes due to the limited number of women in studies, possibly because they are underdiagnosed. Regarding age, mortality was higher in patients over 65 years old. This finding is consistent with the study by Escrutinio et al,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="neither"> which identifies age as a crucial predictor of mortality in patients with SA (HR 1.08, 95% CI 1.07–1.09).</citation_analysis></p>
      <p><citation_analysis attribute="neither">Multiple studies have described the association between SA and cardiovascular diseases.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither"> Albertsen et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="negative"> estimated the risk of developing cardiovascular diseases in 20,240 patients aged ≤50 years, finding that 27.3% developed hypertension within 5 years compared to 15.0% of controls (RR: 1.84; 95% CI: 1.78–1.90). In our study, survival was lower in patients with SA and a history of AMI, CHF, AF, and stroke, with CHF being an independent risk factor for mortality. Heilbrunn et al,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> in a systematic review on the association between SA and the risk of mortality across 22 observational studies, found that SA is a significant risk factor for mortality from cardiovascular diseases (RR 1.94, 95% CI 1.39–2.70). Similar to the results of our study, the impact of cardiovascular disease can be explained by the regulation of the nervous system during the sleep cycle.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="neither"> Brunetti et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="positive"> evaluated the association of SA and AF in patients with cardiovascular disease and found a correlation between the severity of SA and cardiovascular disease but not a causal association between SA and AF. In our study, patients with SA had a higher prevalence of cardiovascular disease risk factors, including CHF, AMI, and AF.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Ioachimescu et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="positive"> reported an accumulated mortality rate of 52.8% (2630/4980) in patients diagnosed with COPD (29%), asthma (7%), and asthma/COPD overlap (15%). The median time to death was 2.7 years (IQR: 0.8–5.7). The mortality rate was significantly higher in men (62.8%) compared to women (34.4%) (p &lt; 0.001). Beaudin et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="positive"> described the prevalence and risk of CKD progression in 1,295 patients with SA. After stratification, 13.6% of the mild SA group, 28.9% of the moderate SA group, and 30.9% of the severe SA group had a moderate to very high risk of CKD progression (p &lt; 0.001). Patients with moderate and severe SA have a higher risk of CKD progression independently of other confounding factors. This is explained by hypoxemia and sleep fragmentation, which activate the sympathetic nervous system and the renin-angiotensin-aldosterone system, favoring hypertension and glomerular hyperfiltration.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Seijo et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="positive"> described a study with 302 patients who underwent SA screening and chest CT scans, finding an 8% higher prevalence of lung cancer in those with an AHI &gt; 15. This difference was statistically significant, assessed using propensity score matching (p = 0.015) and nearest-neighbor matching (p = 0.041). After adjusting for potential confounding factors, a statistically significant association was found between AHI (p = 0.04), nocturnal hypoxemia (including time spent with oxyhemoglobin saturation below 90%, T90; p = 0.005), 3% oxygen desaturation index (p = 0.02), and lung cancer. Conversely, Theorell-Haglöw et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="positive"> conducted a prospective study that did not find an association between SA and cancer mortality (HR 0.997, 95% CI 0.97–1.02, p = 0.85). Although the objective of our study was not to describe a causal association between SA and cancer development, a significant relationship was observed between chronic nocturnal hypoxemia and 5-year mortality in this population.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29–31</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">SA in patients with COPD can be associated with a worse quality of life and greater deterioration in blood oxygen levels due to lung parenchyma impairment and chronic airflow obstruction; this results in disrupted ventilation perfusion and increased susceptibility to desaturation.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> Zhang et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="positive"> reported a prevalence of SA of 44% among 73 COPD patients. The STOP-BANG questionnaire showed worse scores in patients with SA compared to the control group (3.9 vs 3.4; p=0.07), as did the COPD Assessment Test (18.4 vs 15.5; p=0.06). Additionally, nocturnal oximetry demonstrated good accuracy in identifying SA and was independently associated with the AHI in COPD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis></p>
    </sec>
    <sec id="s0006">
      <title>Limitations</title>
      <p><citation_analysis attribute="neither">Among the limitations of our study is its observational nature, with information obtained from clinical records, which may have omissions. However, measures were implemented to minimize information bias, such as continuous training of personnel responsible for data collection. The single-center nature of this research may limit the generalizability of the results. Nevertheless, we believe that the achieved sample size supports the conclusions drawn. Multicenter studies are recommended for a more comprehensive view of survival in SA patients, including a detailed evaluation of treatment adherence.</citation_analysis></p>
    </sec>
    <sec id="s0007">
      <title>Conclusion</title>
      <p><citation_analysis attribute="positive">The study revealed high five-year survival rates, although survival rates were lower when stratified by sex and cardiovascular diseases. Factors associated with decreased overall five-year survival included age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer. While the single-center design of this research may limit the generalizability of the results, these findings are important for incorporating demographic factors and comorbidities into the prognostic evaluation of patients with SA.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p><citation_analysis attribute="neither">The authors are most thankful for the Universidad de La Sabana.</citation_analysis></p>
    </ack>
    <sec sec-type="data-availability" id="s0008">
      <title>Data Sharing Statement</title>
      <p><citation_analysis attribute="neither">The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</citation_analysis></p>
    </sec>
    <sec id="s0009">
      <title>Ethics Approval and Consent to Participate</title>
      <p><citation_analysis attribute="positive">The study was conducted in accordance with the principles of the current Helsinki Declaration, as well as local, regional, and international regulations pertaining to clinical research, including Colombian Law on Biomedical Research. Ethical approval was obtained from the Medical Ethics Committee of the Clínica Universidad de La Sabana (approval number: 202401). Prior to participating in the study, all participants provided written informed consent, and the confidentiality of their data was strictly maintained throughout the study.</citation_analysis></p>
    </sec>
    <sec id="s0010">
      <title>Author Contributions</title>
      <p><citation_analysis attribute="positive">All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</citation_analysis></p>
    </sec>
    <sec sec-type="COI-statement" id="s0011">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors declare no competing interests.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Michael</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sateia</surname>
<given-names>M</given-names></string-name>. <article-title>International classification of sleep disorders-third edition highlights and modifications</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2014</year>;<volume>146</volume>(<issue>5</issue>):<fpage>1387</fpage>–<lpage>1394</lpage>.<pub-id pub-id-type="pmid">25367475</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ge</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Is Obstructive Sleep Apnea Associated with Cardiovascular and All-Cause Mortality?</article-title>
<source><italic toggle="yes">PLoS One</italic></source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<fpage>e69432</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0069432</pub-id><pub-id pub-id-type="pmid">23936014</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peppard</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Barnet</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Palta</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hagen</surname>
<given-names>EW</given-names></string-name>, <string-name><surname>Hla</surname>
<given-names>KM</given-names></string-name>. <article-title>Increased prevalence of sleep-disordered breathing in adults</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2013</year>;<volume>177</volume>(<issue>9</issue>):<fpage>1006</fpage>–<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kws342</pub-id><pub-id pub-id-type="pmid">23589584</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Young</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Finn</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Peppard</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Sleep Disordered Breathing and Mortality: eighteen-Year Follow-up of the Wisconsin Sleep Cohort</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2008</year>;<volume>31</volume>(<issue>8</issue>):<fpage>1071</fpage>–<lpage>1078</lpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD001106.pub3</pub-id><pub-id pub-id-type="pmid">18714778</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Marshall</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>KKH</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>PY</given-names></string-name>, <string-name><surname>Cullen</surname>
<given-names>SRJ</given-names></string-name>, <string-name><surname>Knuiman</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Grunstein</surname>
<given-names>RR</given-names></string-name>. <article-title>Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2008</year>;<volume>31</volume>(<issue>8</issue>):<fpage>1079</fpage>–<lpage>1085</lpage>.<pub-id pub-id-type="pmid">18714779</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Parker</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Newton</surname>
<given-names>GE</given-names></string-name>, et al. <article-title>Influence of Obstructive Sleep Apnea on Mortality in Patients With Heart Failure</article-title>. <source><italic toggle="yes">J Am Coll Cardiol</italic></source>. <year>2007</year>;<volume>49</volume>(<issue>15</issue>):<fpage>1625</fpage>–<lpage>1631</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2006.12.046</pub-id><pub-id pub-id-type="pmid">17433953</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Beaudin</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Raneri</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Ahmed</surname>
<given-names>SB</given-names></string-name>, et al. <article-title>Risk of chronic kidney disease in patients with obstructive sleep apnea</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2022</year>;<volume>45</volume>(<issue>2</issue>):<fpage>zsab267</fpage>.<pub-id pub-id-type="pmid">34757390</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ioachimescu</surname>
<given-names>OC</given-names></string-name>, <string-name><surname>Janocko</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Ciavatta</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Howard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Warnock</surname>
<given-names>MV</given-names></string-name>. <article-title>Obstructive Lung Disease and Obstructive Sleep Apnea (OLDOSA) cohort study: 10-year assessment</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>267</fpage>–<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8180</pub-id><pub-id pub-id-type="pmid">31992433</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Meidan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Elalouf</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Tauman</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Systemic Lupus Erythematous and Obstructive Sleep Apnea: a Possible Association</article-title>. <source><italic toggle="yes">Life</italic></source>. <year>2023</year>;<volume>13</volume>(<issue>3</issue>):<fpage>697</fpage>. doi:<pub-id pub-id-type="doi">10.3390/life13030697</pub-id><pub-id pub-id-type="pmid">36983852</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Benjafield</surname>
<given-names>AV</given-names></string-name>, <string-name><surname>Ayas</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Eastwood</surname>
<given-names>PR</given-names></string-name>, et al. <article-title>Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2019</year>;<volume>7</volume>(<issue>8</issue>):<fpage>687</fpage>–<lpage>698</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30198-5</pub-id><pub-id pub-id-type="pmid">31300334</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tufik</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Santos-Silva</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Taddei</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Bittencourt</surname>
<given-names>LR</given-names></string-name>. <article-title>Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2010</year>;<volume>11</volume>(<issue>5</issue>):<fpage>441</fpage>–<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2009.10.005</pub-id><pub-id pub-id-type="pmid">20362502</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kainulainen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Töyräs</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Oksenberg</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Severity of Desaturations Reflects OSA-Related Daytime Sleepiness Better Than AHI</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2019</year>;<volume>15</volume>(<issue>8</issue>):<fpage>1135</fpage>–<lpage>1142</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.7806</pub-id><pub-id pub-id-type="pmid">31482835</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Martinez-Garcia</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Sánchez-de-la-Torre</surname>
<given-names>M</given-names></string-name>, <string-name><surname>White</surname>
<given-names>DP</given-names></string-name>, <string-name><surname>Azarbarzin</surname>
<given-names>A</given-names></string-name>. <article-title>Hypoxic Burden in Obstructive Sleep Apnea: present and Future</article-title>. <source><italic toggle="yes">Arch Bronconeumol</italic></source>. <year>2023</year>;<volume>59</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arbres.2022.08.005</pub-id><pub-id pub-id-type="pmid">36115739</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Paschou</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Bletsa</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Saltiki</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes</article-title>. <source><italic toggle="yes">Nutrients</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>23</issue>):<fpage>4989</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu14234989</pub-id><pub-id pub-id-type="pmid">36501019</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yeghiazarians</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jneid</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tietjens</surname>
<given-names>JR</given-names></string-name>, et al. <article-title>Obstructive Sleep Apnea and Cardiovascular Disease: a Scientific Statement From the American Heart Association</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2021</year>;<volume>144</volume>(<issue>3</issue>):<fpage>e56</fpage>–<lpage>e67</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIR.0000000000000988</pub-id><pub-id pub-id-type="pmid">34148375</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kapur</surname>
<given-names>VK</given-names></string-name>, <string-name><surname>Auckley</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Chowdhuri</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: an American Academy of Sleep Medicine Clinical Practice Guideline</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>479</fpage>–<lpage>504</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6506</pub-id><pub-id pub-id-type="pmid">28162150</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Harris</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Minor</surname>
<given-names>BL</given-names></string-name>, et al. <article-title>The REDCap consortium: building an international community of software platform partners</article-title>. <source><italic toggle="yes">J Biomed Inform</italic></source>. <year>2019</year>;<volume>95</volume>:<fpage>103208</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jbi.2019.103208</pub-id><pub-id pub-id-type="pmid">31078660</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="book"><string-name><surname>Hosmer</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Lemeshow</surname>
<given-names>S</given-names></string-name>. <source><italic toggle="yes">Applied Logistic Regression</italic></source>. <edition>2nd</edition> ed. <publisher-loc>New York, New York</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Inc</publisher-name>; <year>2000</year>:<fpage>162</fpage>.</mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bouscoulet</surname>
<given-names>LT</given-names></string-name>, <string-name><surname>Vázquez-García</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Muiño</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Prevalence of sleep related symptoms in four Latin American cities</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2008</year>;<volume>4</volume>(<issue>6</issue>):<fpage>579</fpage>–<lpage>585</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.27353</pub-id><pub-id pub-id-type="pmid">19110888</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jara</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Phipps</surname>
<given-names>AI</given-names></string-name>, <string-name><surname>Maynard</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Weaver</surname>
<given-names>EM</given-names></string-name>. <article-title>0565 Long-Term Survival in Veterans with Sleep Apnea</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2018</year>;<volume>41</volume>(<issue>1</issue>):<fpage>A210</fpage>–<lpage>A211</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsy061.564</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jennum</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tønnesen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ibsen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kjellberg</surname>
<given-names>J</given-names></string-name>. <article-title>All-cause mortality from obstructive sleep apnea in male and female patients with and without continuous positive airway pressure treatment: a registry study with 10 years of follow-up</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2015</year>;<volume>7</volume>:<fpage>43</fpage>–<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S75166</pub-id><pub-id pub-id-type="pmid">25914563</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Scrutinio</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Guida</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Aliani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Castellana</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Guido</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Carone</surname>
<given-names>M</given-names></string-name>. <article-title>Age and comorbidities are crucial predictors of mortality in severe obstructive sleep apnoea syndrome</article-title>. <source><italic toggle="yes">Eur J Intern Med</italic></source>. <year>2021</year>;<volume>90</volume>:<fpage>71</fpage>–<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejim.2021.04.018</pub-id><pub-id pub-id-type="pmid">33975770</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Heilbrunn</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Ssentongo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chinchilli</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Oh</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ssentongo</surname>
<given-names>AE</given-names></string-name>. <article-title>Sudden death in individuals with obstructive sleep apnoea: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">BMJ Open Respir Res</italic></source>. <year>2021</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e000656</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjresp-2020-000656</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Salari</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Khazaie</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Abolfathi</surname>
<given-names>M</given-names></string-name>, et al. <article-title>The effect of obstructive sleep apnea on the increased risk of cardiovascular disease: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2022</year>;<volume>43</volume>(<issue>1</issue>):<fpage>219</fpage>–<lpage>231</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-021-05765-3</pub-id><pub-id pub-id-type="pmid">34797460</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Albertsen</surname>
<given-names>IE</given-names></string-name>, <string-name><surname>Bille</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Piazza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lip</surname>
<given-names>GYH</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>PB</given-names></string-name>. <article-title>Cardiovascular Risk in Young Patients Diagnosed With Obstructive Sleep Apnea</article-title>. <source><italic toggle="yes">J Am Heart Assoc</italic></source>. <year>2024</year>;<volume>13</volume>(<issue>8</issue>):<fpage>e033506</fpage>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.123.033506</pub-id><pub-id pub-id-type="pmid">38563371</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zisapel</surname>
<given-names>N</given-names></string-name>. <article-title>New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation</article-title>. <source><italic toggle="yes">Br J Pharmacol</italic></source>. <year>2018</year>;<volume>175</volume>(<issue>16</issue>):<fpage>3190</fpage>–<lpage>3199</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bph.14116</pub-id><pub-id pub-id-type="pmid">29318587</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ishikawa</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Oks</surname>
<given-names>M</given-names></string-name>. <article-title>Central Sleep Apnea</article-title>. <source><italic toggle="yes">Clin Geriatr Med</italic></source>. <year>2021</year>;<volume>37</volume>(<issue>3</issue>):<fpage>469</fpage>–<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cger.2021.04.009</pub-id><pub-id pub-id-type="pmid">34210451</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Brunetti</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Testani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Losurdo</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Association of Obstructive Sleep Apnea and Atrial Fibrillation in Acute Ischemic Stroke: a Cross-Sectional Study</article-title>. <source><italic toggle="yes">J Pers Med</italic></source>. <year>2023</year>;<volume>13</volume>(<issue>3</issue>):<fpage>527</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jpm13030527</pub-id><pub-id pub-id-type="pmid">36983709</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Seijo</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Pérez-Warnisher</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Giraldo-Cadavid</surname>
<given-names>LF</given-names></string-name>, et al. <article-title>Obstructive sleep apnea and nocturnal hypoxemia are associated with an increased risk of lung cancer</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2019</year>;<volume>63</volume>:<fpage>41</fpage>–<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2019.05.011</pub-id><pub-id pub-id-type="pmid">31605903</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Theorell-Haglöw</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wittert</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Does obstructive sleep apnea increase the risk of cancer and cancer mortality in combined community-based cohorts?</article-title>
<source><italic toggle="yes">J Sleep Res</italic></source>. <year>2023</year>;<volume>33</volume>(<issue>4</issue>):<fpage>e14089</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.14089</pub-id><pub-id pub-id-type="pmid">37990480</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nautiyal</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Arya</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Sleep Attributes Influencing Cardiovascular Morbidity Among Young Adults Pursuing Professional Courses in Dehradun, India: a Cross-Sectional Study</article-title>. <source><italic toggle="yes">Cureus</italic></source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>e52647</fpage>. doi:<pub-id pub-id-type="doi">10.7759/cureus.52647</pub-id><pub-id pub-id-type="pmid">38380200</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>XL</given-names></string-name>, <string-name><surname>Dai</surname>
<given-names>HP</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Obstructive Sleep Apnea in Patients With Fibrotic Interstitial Lung Disease and COPD</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2019</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1807</fpage>–<lpage>1815</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8090</pub-id><pub-id pub-id-type="pmid">31855166</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bouloukaki</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Fanaridis</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Testelmans</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pataka</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Schiza</surname>
<given-names>S</given-names></string-name>. <article-title>Overlaps between obstructive sleep apnoea and other respiratory diseases, including COPD, asthma and interstitial lung disease</article-title>. <source><italic toggle="yes">Breathe</italic></source>. <year>2022</year>;<volume>18</volume>(<issue>3</issue>):<fpage>220073</fpage>. doi:<pub-id pub-id-type="doi">10.1183/20734735.0073-2022</pub-id><pub-id pub-id-type="pmid">36865659</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
